Rosen Law Probes Simulations Plus Over Q3 Sales and Preliminary Revenue Disclosures
- Rosen Law investigates whether Simulations Plus misled investors after disclosing its Q3 2025 results and preliminary sales.
- Simulations Plus reported Q3 sales $20.4M (10% YoY), below consensus $20.9M; June-quarter prelim $19–20M vs $22.78M.
- Probe questions Simulations Plus' demand reporting, forecasting controls, and disclosures, with possible legal and governance consequences.
Investigation Questions Simulations Plus’ Sales Disclosures and Demand Outlook
Rosen Law Firm is investigating potential securities claims accusing Simulations Plus Inc. of issuing materially misleading business information after its third-quarter 2025 results and earlier preliminary sales figures. Published reports during market hours on July 15, 2025 highlight that Simulations Plus reports $20.4 million in third-quarter sales, a 10% year‑over‑year increase but below a consensus estimate of $20.9 million, and that preliminary June-quarter sales had been disclosed in a $19.0 million to $20.0 million range versus a consensus of $22.78 million. Rosen Law’s inquiry focuses on whether the company’s public statements and disclosure practices properly reflected demand conditions and the accuracy of its sales guidance.
The probe places a spotlight on how Simulations Plus communicates commercial performance and near‑term outlook in an industry where contract timing and renewal visibility affect reported revenue. Simulations Plus provides modeling, simulation and predictive software used by pharmaceutical and biotech companies for drug development decisions; revenue patterns in that sector can be affected by timing of licensing deals, software renewals and professional services engagements. Allegations that the company mischaracterized demand or guidance raise questions about internal forecasting controls and the sufficiency of disclosures to customers, partners and securities holders.
Beyond potential legal exposure, the investigation prompts broader scrutiny of corporate governance and disclosure policies at vendors to the life‑sciences sector. If regulators or courts find deficiencies in how results or preliminary figures are reported, Simulations Plus may need to strengthen internal revenue recognition controls, enhance forward‑looking statement clarity, and revise investor communications. The situation also underscores the importance for software and services firms in life sciences to align sales reporting cadence with the expectations of their client base and the market for scientific software.
Shareholder Action and How to Participate
Rosen Law is soliciting potential class members who purchased Simulations Plus securities and believes they may be entitled to compensation through a contingency‑fee class action prepared without out‑of‑pocket fees. Interested investors are invited to submit information at https://rosenlegal.com/submit-form/?case_id=42476 or https://rosenlegal.com/submit-form/?case_id=42439, call toll‑free 866‑767‑3653, or email [email protected] for details.
Firm Background and Counsel Selection
Rosen Law emphasizes its experience in securities class actions and shareholder derivative litigation, noting prior large recoveries and industry rankings, and urges investors to select experienced counsel. The firm highlights accolades including top rankings by ISS Securities Class Action Services and recognitions from Law360, Lawdragon and Super Lawyers.